Search Results

Apogenix’ Asunercept Demonstrates Efficacy in Phase II Trial for the Treatment of Hospitalized COVID-19 Patients

Apogenix, a biopharmaceutical company developing next generation immunotherapeutics, announced today that asunercept showed statistically significant benefits for hospitalized COVID-19 patients in the ASUNCTIS trial.

October 19, 2022

·

5 min read

Apogenix Enrolls First Patients in Pivotal Phase III Trial for the Treatment of Hospitalized COVID-19 Patients with Asunercept

The ASUCOV trial assesses efficacy and safety of asunercept on top of standard of care Over 600 patients to be enrolled at 50 trial sites in Europe, India, and South Africa Trial funded by the German Federal Government and dievini Hopp BioTech

December 14, 2022

·

4 min read

Drug Development

Apogenix to Start European Clinical Phase II Trial with Asunercept in COVID-19 Patients

Apogenix, a biopharmaceutical company developing next generation immunotherapeutics, announced today that it has received regulatory approval to start a clinical phase II trial with asunercept in COVID-19 patients in Russia.

July 28, 2020

·

3 min read

Deals

Apogenix to Present at Several Upcoming International Conferences

Apogenix, a biopharmaceutical company developing next generation immuno-oncology therapeutics, announced that it will attend several upcoming international conferences.

October 15, 2019

·

2 min read

Apogenix to Present New Data on Asunercept at ESMO Immuno-Oncology Congress

Apogenix announced that new data on its lead immuno-oncology candidate asunercept will be presented in a poster at the ESMO Immuno-Oncology Congress 2019, held from December 11-14, 2019, at the Palexpo in Geneva, Switzerland.

December 5, 2019

·

1 min read

Apogenix to Present at Four Upcoming International Conferences

Apogenix announced that it will present updates on its three most advanced HERA-ligands as well as lead drug candidate asunercept at four upcoming international conferences.

May 7, 2019

·

4 min read

Apogenix to Present New Data on Asunercept at ESMO Immuno-Oncology Congress

Apogenix, a biopharmaceutical company developing next generation immuno-oncology therapeutics, announced today that new data on its lead immuno-oncology candidate asunercept will be presented in a poster at the ESMO Immuno-Oncology Congress 2019, held from December 11-14, 2019, at the Palexpo in Geneva, Switzerland.

December 5, 2019

·

1 min read

ESMO and Apogenix Collaborate on “Recurrent Glioblastoma Management: Challenges and Opportunities” Colloquium

Apogenix, a biopharmaceutical company developing next generation immuno-oncology therapeutics, announced that it will be supporting a colloquium titled “Recurrent Glioblastoma Management: Challenges and Opportunities” at this year’s ESMO Congress, held from September 27 to October 1 at the Fira Gran Via in Barcelona, Spain.

September 25, 2019

·

2 min read

Drug Development

Publication in Cancer Management and Research Underlines the Potential of Apogenix’ Asunercept for the Treatment of Other Malignancies Beyond Glioblastoma and MDS

Apogenix announced that a new publication in Cancer Management and Research[1] reviews asunercept as a promising treatment option for patients with other malignancies beyond glioblastoma and myelodysplastic syndromes.

September 4, 2019

·

4 min read

Publication in Cancer Management and Research Underlines the Potential of Apogenix’ Asunercept for the Treatment of Other Malignancies Beyond Glioblastoma and MDS

Apogenix announced that a new publication in Cancer Management and Research[1] reviews asunercept as a promising treatment option for patients with other malignancies beyond glioblastoma and myelodysplastic syndromes.

September 4, 2019

·

4 min read